Full Text View
Tabular View
No Study Results Posted
Related Studies
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
This study has been completed.
Study NCT00032110   Information provided by National Cancer Institute (NCI)

First Received on March 8, 2002.   Last Updated on January 23, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Colonic Neoplasms
Colorectal Neoplasms
Rectal Neoplasms
More general conditions related to this trial
Carcinoma
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Rectal Diseases
Interventions listed in this trial
erlotinib hydrochloride
pharmacological study
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services